3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
141
Nivolumab
117
Ipilimumab
69
Cyclophosphamide
34
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
fludarabine
22
binimetinib
22
Interleukin-2
21
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
aldesleukin
16
CTLA-4 Antigen
16
fludarabine phosphate
15
cemiplimab
15
atezolizumab
15
Radiosurgery
15
Opdualag
14
Radiotherapy
11
lifileucel
10
lenvatinib
10
Blood Specimen Collection
10
spartalizumab
8
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Interleukin-15
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled